Something magical has been happening in Cambridge’s Kendall Square for years. All kinds of biotech companies, big and small, have thrived on it. Now the big guys have to be careful not to squeeze the life out of it.
The biotech real estate market in Kendall Square is about as hot as it gets. Genzyme is building a new headquarters along what a spokesman calls “the biotech Champs-Elysees.” Biogen, after a brief foray in the suburbs, keeps gobbling up more space. Alnylam Pharmaceuticals ambitiously planted its flag on a nearby property, and, quietly, snagged first dibs to bid for the house that Henri built–Genzyme’s iconic, glassy headquarters. After realizing that many isolated suburban campuses are a dead zone for drug discovery, giants like Pfizer, Novartis and others have decided over the past 10 years that they’ve just gotta weave themselves into that web around Kendall Square, near MIT.